Background
==========

With identification of 4292,000 new cases, and 2814,000 cancer related deaths in the year 2015, lung cancer remains the most common malignant tumor type and the leading cause of cancer deaths in China [@B1]. Based on different biological and morphological characteristics, lung cancer is categorized into two major types; Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Among these, SCLC accounts for approximately 15% of all lung cancers [@B2], and is typically characterized by its highly aggressive nature and early tendency to distant metastasis [@B3]. The Veteran Affairs Lung Study Group (VALSG) classification further categorized SCLC patients into limited stage (LS) and extensive stage (ES) [@B4]. Unfortunately, due to the development of frequent chemotherapeutic resistance, most LS-SCLC patients, and nearly all ES-SCLC patients, suffer from recurrence and progression, and subsequently result in their poor prognosis [@B5], [@B6]. Moreover, due to existence of heterogeneity and variable clinical characteristics, the SCLC prognosis can vary among different patients. Therefore, it is critical and necessary to find an appropriate individual stratified variable, which can help to guide better anti-tumor and palliative treatment options in SCLC patients.

It is widely recognized that variations in patient prognosis in cancer are not solely determined by tumor characteristics, but patient-response factors also play an important role [@B7]. Over the years, it has increasingly been evident that cancer-associated inflammation, especially the host systemic inflammation response, show close association with disease development and progression, along with patient survival in cancers [@B8], [@B9]. Concurrently, the levels of acute-phase proteins, like C-reactive protein (CRP) and albumin (ALB) are assessed in the plasma to evaluate the degree of systemic inflammation [@B10]. In addition, multiple studies have also demonstrated about the prognostic power of these factors in variety of cancers, independent of disease stage, performance status and clinical characteristics [@B11]. Besides, some cellular components of the inflammatory response, including lymphocytes and neutrophils, have also been reported to depict predictive value in the outcome of patients with malignant tumors [@B12], [@B13].

Interestingly, it was realized early on that combining these factors into some kind of systemic inflammatory based scores, can greatly help to develop some independent prognostic value. Among them, modified Glasgow Prognostic Score (mGPS), which consist of CRP and ALB concentrations, was regarded as a prominent prognostic factor in most cancers [@B14]. Also, the prognostic nutritional index (PNI), calculated based on albumin level and total lymphocyte count, was also effective at predicting overall survival [@B15]. Similarly, neutrophil-to-lymphocyte ratio (NLR) was also noticed to be beneficial in predicting the survival in solid tumors [@B16].

In recent years, several studies have indicated that host response to systemic inflammation is still an important factor in determining the clinical outcomes in SCLC patients [@B17], [@B18]. Indeed, our previous studies have also concluded that such systemic inflammation based prognostic scores, including mGPS, CRP/ALB and PNI, were useful in predicting cancer-specific survival in SCLC patients [@B19]-[@B21]. Because of the objectivity, reliability and accessibility of these systemic inflammation based prognostic scores, it is obvious that their use can be adapted in clinical settings, and can help to stratify SCLC patients. However, to our knowledge, no direct comparison of the longitudinal measurements of these systemic inflammation based prognostic scores has been undertaken in SCLC.

Therefore, the present study was planned to compare the prognostic value of selected systemic inflammation response markers in SCLC patients, and also identify a most appropriate systemic inflammation based prognostic score.

Methods
=======

Patients
--------

Patients with histologically confirmed SCLC, between January 2006 and December 2011, at Sun Yat-sen University Cancer Center, were included in our study. Other eligible selection criteria were as follows: (a) patients displaying Eastern Cooperative Oncology Group performance status (PS) of 2 or less; (b) are older than 18 years; (c) had available pre-treatment laboratory data, consisting of CRP and ALB levels, along with lymphocyte and neutrophil counts; (d) displayed normal liver function; and (e) had sufficient clinical information. However, the patients were excluded if they; (a) had other types of cancers; (b) had liver disease; (c) had clinical evidence of infection; and (e) had autoimmune disease. The written informed consent was obtained from each patient before the start of study.

Biomarkers and other variables
------------------------------

CRP, total protein, albumin, neutrophil count, and lymphocyte count, considered as biomarkers of systemic inflammation response were measured from the patient\'s blood samples, collected before the initial treatment. The detailed scoring criteria were summarized in Supplementary Table [S1](#SM0){ref-type="supplementary-material"}.

The mGPS was calculated as follows [@B22]: CRP≤10mg/L=0,CRP\>10mg/L=1, CRP\>10mg/L and albumin \<35g/L=2. The CRP/ALB ratio was calculated by dividing the CRP level by albumin level [@B23].

The AGR was defined as follows [@B24]:

AGR= albumin (g/L) / (total protein- albumin) (g/L)

The PNI was calculated as follows [@B25]:

PNI= 10×albumin (g/L) + 0.005×lymphocyte count (10

9

/L)

The ALI was calculated with the following formula [@B26]:

ALI= BMI (Kg/m

2

)×albumin (g/L) / ( neutrophil count/ lymphocyte count)

The information about other baseline clinical characteristics, consisting of demographic information, performance status (PS), smoking status, body mass index (BMI), cancer stage and therapeutic information, was also collected. The smokers were defined as patients who had more than 100 cigarettes. The SCLC staging was determined according to VALG staging system.

Treatment and patient follow-up
-------------------------------

The most frequent chemotherapy administered to the patients consisted of platinum plus etoposide, on day 1 through 3, for 4 or 6 cycles, after every 3 weeks. Some patients even received thorax radiotherapy (TRT) along with chemotherapy. Furthermore, several patients subsequently underwent prophylactic cranial irradiation (PCI).

All the enrolled patients were carefully assessed for therapy response after every two cycles of treatment, using dynamic computed tomography (CT) scan. After completion of the anti-tumor treatment, patients received CT scan every 2 months thereafter, or at the time when any symptoms of possible progression were observed. Tumor response evaluation was carried out according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patient overall survival (OS) was defined as the period from the time of pathological diagnosis to the date of death for any cause or last follow-up. Patients who didn\'t die at the date of cutoff were censored, and the last follow-up date was December 2017.

Statistical analysis
--------------------

The primary outcome of our study was overall survival. Pearson correlation, Chi-square test, and Fisher exact test were used to compare continuous and categorical variables. Kaplan-Meier method was used to estimate the probability of survival, and log- rank test was performed to assess survival difference. The predictive power of potential prognostic variables, including sex, PS, cancer stage, mGPS, CRP/ALB, AGR, PNI, as well as ALI, were assessed using Cox proportional hazards model. The optimal cut-off value of CRP/ALB, AGR, PNI and ALI were determined using an R software-engineered, web-based system designed by Budczies J *et al.* (<http://molpath.charite.de/cutoff/>) [@B27]. The P value of less than 0.05 represented statistically significant difference. All of the statistical tests were two-tailed and all statistical analyses were performed using SPSS statistical software package (version 21.0, IBM, Armonk, NY).

Results
=======

Patients Characteristics
------------------------

A total of 591 SCLC diagnosed patients were reviewed at our center, and among them 46 patients did not have any baseline data about patient height or weight, while 94 patients had no information about pre-treatment CRP levels. Therefore, only 451 eligible SCLC patients were included for further analysis in our study (Figure [1](#F1){ref-type="fig"}).

The baseline characteristics of all these patients have been shown in Table [1](#T1){ref-type="table"}. Overall, the median age of patients was 60 years (range: 19-82 years), and majority of them were male (86.3%, 389 of 451 patients), smokers (82.0%, 370 of 451 patients), and displayed limited stage disease (55.4%, 250 of 451 patients) as characterized by VALG criteria. Eastern Cooperative Oncology Group PS was 0 in 257 patients (57.0%), 1 in 158 patients (35.0%), and 2 in 36 patients (18.0%). In addition, 85.4% (n=385) patients received etoposide-based chemotherapy regimen, while 75 (29.9%) patients had TRT, and another 64 (25.5%) patients received PCI after chemotherapy.

Correlation between patient survival and clinicopathological characteristics
----------------------------------------------------------------------------

During the follow-up period, 306 (67.8%) of the total patients died, and the observed median OS of enrolled patients was 15.6 months (range: 0.03-92.03 months). The relationship between clinicopathological characteristics of SCLC patients and their survival has been summarized in Table [1](#T1){ref-type="table"}. The univariate survival analysis showed following parameters as significantly associated with overall survival; PS (*P*\<0.001), LDH level (*P*\<0.001), tumor stage (*P*\<0.001), and TRT (*P*=0.003). Further, multivariate analysis only confirmed PS (*P*\<0.001), LDH level (*P*=0.002) and tumor stage (*P*\<0.001) as independent prognostic factors related with cancer survival.

Correlation between patient survival and inflammation biomarkers
----------------------------------------------------------------

In addition, we assessed the prognostic power of CRP, ALB, Neutrophil (NE), and lymphocyte (LY), with an intency to identify the association between patient survival and systemic inflammation biomarkers. Based on the biostatistical tool Cutoff Finder, the optimal cutoff values of CRP, ALB, NE, LY were 5.8, 36.0, 5.0, and 1.8 for OS, respectively. The univariate survival analysis demonstrated elevated CRP (*P*\<0.001) and NE (*P*=0.010) levels, along with reduced ALB (*P*\<0.001) and LY (*P*=0.023) levels, to be significantly associated with poor cancer-specific survival (Supplemental Figure [1](#SM0){ref-type="supplementary-material"}). However, multivariate analysis only validated CRP \[hazard ratio (HR) 1.32, 95% CI 1.03-1.70, *P*=0.032\] and ALB (HR 1.77, 95% (CI) 1.19-2.64, *P*=0.005) levels to be independently associated with cancer-specific survival.

Correlation between patient survival and systemic inflammation-based prognostic scores
--------------------------------------------------------------------------------------

As independent prognostic values of CRP and ALB have been shown above, through both univariate and multivariate analyses, we next tried to explore the potential predictive power of systemic inflammation-based prognostic scores calculated based on CRP and/or ALB levels.

### mGPS

A total of 273 (60.5%) SCLC patients had mGPS of 0, while 162 (35.9%) patients had mGPS of 1. Only 16 (3.5%) patients displayed mGPS of 2 at baseline (Table [2](#T2){ref-type="table"}). Importantly, the patients with mGPS of 2 displayed 2.2 months of OS, and this OS period was significantly less in comparison to patients with mGPS of 0 and 1, with OS of 19.4 and 15.9 months, respectively (*P*\<0.001) (Figure [2](#F2){ref-type="fig"}A). Interestingly, multivariate analysis revealed an independent association between mGPS (HR 5.53, 95% CI 3.17-9.66, *P*\<0.001) and OS in SCLC patients (Table [2](#T2){ref-type="table"}).

### CRP/ALB

The observed optimal cutoff point of CRP/ALB for OS was 0.44 (range: 0.00-10.40). Based on this, the patients were divided into two groups: Group 1 consisted of 319 (70.7%) patients with CRP/ALB value of ≤0.44, while group 2 with CRP/ALB value of \>0.44 had 132 (29.3%) patients (Table [2](#T2){ref-type="table"}). The univariate survival analysis displayed that elevated CRP/ALB ratio correlated with lower OS time (13.6 months at CRP/ALB\> 0.44 vs. 19.6 months at CRP/ALB≤0.44) (*P*\<0.001) (Figure [2](#F2){ref-type="fig"}B). Multivariate survival analysis further confirmed that patients with elevated CRP/ALB ratio of \>0.44, had 1.41 times higher risk of death (HR 1.41, 95% CI 1.10-1.81, *P*=0.007) (Table [2](#T2){ref-type="table"}).

### AGR

The optimal cutoff level of AGR for patient OS was observed to be 1.25 (range: 0.16-4.94). Based on this cutoff value, 93 (20.6%) patients were in the low AGR group, while remaining 358 (79.4%) patients were in high AGR group (Table [2](#T2){ref-type="table"}). Univariate analysis showed that overall patients survival in high AGR group was much longer than in low AGR group (19.6 months vs. 15.6 months, *P*\<0.001) (Figure [3](#F3){ref-type="fig"}A). Multivariate analysis showed AGR as an independent prognostic factor in SCLC (HR 1.35, 95% CI 1.02-1.77, *P*=0.034) (Table [2](#T2){ref-type="table"}).

### PNI

With PNI optimal cutoff level of 37.5 (range: 13.5-52.5) for OS, 387 (85.8%) patients were categorized into high PNI group, and 64 (14.2%) were part of low PNI group (Table [2](#T2){ref-type="table"}). Based on univariate analysis, high PNI was observed to be significantly associated with better OS, in comparison to low PNI (18.9 months vs. 12.1 months, *P*\<0.001) (Figure [3](#F3){ref-type="fig"}B). Multivariate analysis also established independent association of PNI with overall survival (HR 1.19, 95% CI 1.02-1.39, *P*=0.026) (Table [2](#T2){ref-type="table"}).

### ALI

Based on the ALI optimal cutoff value of 47.0 (range: 4.2-544.6) for OS, the patients were divided into two groups: ALI ≤47.0 (n=341, 75.6%) and ALI \> 47.0 (n=110, 24.4%) (Table [2](#T2){ref-type="table"}). The univariate analysis showed negative association between low ALI and OS (25.6 months at ALI \> 47.0 vs. 16.5 months at ALI ≤47.0, *P*\<0.001) (Figure [3](#F3){ref-type="fig"}C). However, multivariate analysis did not reveal ALI as an independent predictor of overall survival in SCLC (*P*=0.172) (Table [2](#T2){ref-type="table"}).

Comparison of systemic inflammation-based prognostic scores
-----------------------------------------------------------

Finally, to compare the prognostic power of these systemic inflammation-based prognostic scores, we performed survival analysis based on cancer stage stratification. Our data showed that prognostic values of mGPS (*P*\<0.001), AGR (*P*\<0.001), PNI (*P*=0.001) and ALI (*P*\<0.001) had significant association with patients at extension stage, but not at limited stage (*P*=0.092, *P*=0.171 and *P*=0.620, respectively). In contrast, the association between CRP/ALB and OS was noted in both extensive (*P*=0.013) and limited stage (*P*=0.005) patients (Figure [4](#F4){ref-type="fig"}). In addition, we also performed ROC curve analysis, and compared the AUC values to evaluate the differentiation ability of each systemic inflammation-based prognostic score. The CRP/ALB score displayed higher AUC value in comparison to mGPS, AGR, PNI, and ALI scores (Figure [5](#F5){ref-type="fig"}) (*P*=0.023).

Discussion
==========

The links between systemic inflammation and cancer have been explored widely for decades, because epidemiological observation have indicated that inflammatory markers are evident in the tumor microenvironment, and tumors are frequently formed at the sites of chronic inflammation [@B28]. Recent studies have clearly suggested about the obvious relationships between systemic inflammatory response markers and tumor patients poor outcome [@B29], [@B30]. More specifically, our study also confirmed the link of C-reactive protein and hypoalbuminemia with SCLC patient survival, but the molecular mechanism of their role is still not elucidated.

Importantly, our study established that in comparison to the cellular components of white cell counts (lymphocyte and neutrophil), the acute phase proteins (C-reactive protein and albumin) consistently have independent prognostic value. This would mean that markers like mGPS, CRP/ALB and AGR, which were calculated based on C-reactive protein and albumin levels, were definitely superior to those cellular components, including PNI and ALI, in predicting SCLC patient\'s survival. We believe that our study is the first, which offered detailed insight into systemic inflammation-based prognostic scores in SCLC patients.

In addition, our study also demonstrated association of systemic inflammatory response with cancer-specific survival in patients with small cell lung cancer. The association of systemic inflammation-based prognostic scores, including mGPS, AGR, CRP/ALB, and PNI with cancer-specific survival in SCLC patients, was consistent with previously published studies in other tumor types [@B23], [@B31]-[@B33]. To further identify a most appropriate systemic inflammation-based prognostic score, we performed a longitudinal comparison of these prognostic scores in SCLC patients, and subgroup analysis based on disease stage demonstrated that the prognostic power of CRP/ALB ratio was remarkable in both limited and extensive stage patients. However, the prognostic scores of other markers like, mGPS, AGR, and PNI too showed significant prognostic abilities in extensive stage patients, but did not show same prognostic power in limited stage patients. It is important to note that mGPS revealed some prognostic tendency in limited stage patients, but the results were insignificant.

The CRP/ALB ratio was calculated based on the laboratory measurement of CRP and albumin levels. Some studies have revealed that SCLC patients have higher levels of CRP in comparison to non-malignant subjects, and show association with worse patient outcome [@B34], [@B35]. Albumin is often considered as a marker for nutritional status of patients in clinic [@B36], and recent studies have indicated that low baseline albumin levels not only have strong relationship with tumor progression, but also with poor overall survival in lung cancer [@B37], [@B38]. However, the biological mechanism of association between CRP, albumin and increased risk of cancer development is not clear. In this context, it is first hypothesized that CRP increase and albumin decrease is probably regulated by proinflammatory cytokines, especially interleukin (IL)-6 and IL-1. These cytokines are also crucial for neoangiogenesis and disease progression, and thus are significantly associated with the increasing risk of lung cancer development [@B39], [@B40]. Second, an elevated CRP and reduced albumin levels correlates with increase in weight loss, fatigue and lean tissue, thereby probably resulting in poor performance status and survival in various cancer types [@B41], [@B42].

Interestingly, ROC analysis suggested that AUC value of CRP/ALB was higher than mGPS, AGR, and PNI for overall survival, which implied that CRP/ALB ratio has powerful predictive value, in comparison to other inflammation-based prognostic scores. Additionally, it was also noticed that CRP/ALB ratio, based on its outstanding prognostic power, had the ability to stratify SCLC patients\' outcome at diagnosis. Moreover, since ROC analysis indicated higher values for CRP/ALB ratio and mGPS than AGR and PNI, this clearly show that CRP and albumin have higher prognostic value than white cell count based prognostic scores, whether they contain albumin or not. Consistent with this observation, a previous study has also identified that CRP based prognostic scores were more powerful than other inflammation-based prognostic scores, in patients with different tumor types [@B43].

The study by Temel *et al.* has highlighted the importance of clinicians, in deciding which patients will receive subsequent therapy, and who would receive only palliative care [@B44]. In fact the clinicians are the one who will make decision about the quality of life and anti-tumor therapy administration in cancer patients. Thus, they importantly need an appropriate prognostic marker, which will subsequently help them to predict between the patients response and the value of anti-tumor therapy. In this context, our study clearly suggested that CRP/ALB ratio is the marker that is powerful enough to act as prognostic score in SCLC patients. The other advantage of CRP/ALB ratio as a prognostic score is economical, as it is based only on two baseline laboratory makers, which are simple and inexpensive. Thus, it can be really helpful in improving SCLC patients stratification.

Finally, our study also has some limitations, including it being a retrospective and single center study, and thus has the potential to suffer from selection bias. However, to reduce the bias, we have recruited consecutive patients. Moreover, multivariate analysis showed CRP/ALB as an independent prognostic factor, after adjustment for other clinical characteristics. Therefore, a multi-center and large-scale prospective validation study would be essentially required to establish these findings independently.

Overall, our study concluded that systemic inflammation response makers are vital predictors of overall survival in SCLC patients. Especially, we observed that CRP/ALB ratio is not only an independent prognostic marker, but also seems to be most optimal score, among all other analyzed systemic inflammation-based prognostic scores, in terms of its predictive power of SCLC patient survival. In addition, CRP/ALB ratio appears to be cost-effective prognostic factor, and can be easily adapted in the clinical practice to stratify the patients for future clinical trials.
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###### 

Basic characteristic of all patients and univariate survival analysis

  ---------------------------------------------------------------------------------------------------------
  Variables                  Cases,\      Proportion, %   Median OS, months (95% CI)   *P* value         
                             *N*                                                                         
  -------------------------- ------------ --------------- ---------------------------- ----------- -- -- --
  **Age, years**             60 (19-82)   0.468                                                          

  **Gender**                                                                                             

  Male                       389          86.3            17.9(16.52-19.28)            0.418             

  Female                     62           13.7            18.7(13.63-23.77)                              

  **Smoking**                                                                                            

  Smoker                     370          82.0            18.5(17.05-20.02)            0.392             

  Never-smoker               81           18.0            16.7(13.95-19.45)                              

  **Disease stage**                                                                                      

  Limited stage              251          55.7            25.4(20.01-30.73)            \< 0.001          

  Extensive stage            200          44.3            14.2(11.67-16.67)                              

  **PS**                                                                                                 

  0                          257          57.0            19.2(17.49-20.91)            \< 0.001\         

  1                          158          35.0            18.7(16.63-20.70)                              

  2                          36           8.0             9.3(8.06-10.61)                                

  **TRT**                                                                                                

  Yes                        171          62.1            19.0(17.50-20.57)            0.003             

  No                         280          37.9            13.6(17.50-20.57)                              

  **LDH, U/L**                                                                                           

  \<245                      282          62.5            19.8(17.15-22.45)            \< 0.001          

  ≥245                       169          37.5            13.1(10.88-15.32)                              

  **Chemotherapy regimen**                                                                               

  Etoposide-based            385          85.4            18.4(16.64-20.09)            0.953             

  Others                     66           14.6            17.5(15.03-19.91)                              

  **PCI**                                                                                                

  Yes                        107          23.7            18.6(16.24-21.02)            0.457             

  No                         344          76.3            18.0(16.31-19.76)                              

                                                                                                         
  ---------------------------------------------------------------------------------------------------------

###### 

Results from Cox Regression Model (Adjusted for mGPS, CRP/ALB, AGR, PNI, ALI)

  Variables     Hazard Ratio   95% CI   *P* value   
  ------------- -------------- -------- ----------- ---------
  **mGPS**                                          
  0             1.00           \-       \-          \-
  1             1.34           0.89     1.45        0.293
  2             5.53           3.17     9.66        \<0.001
  **CRP/ALB**                                       
  \>0.44        1.00           \-       \-          \-
  ≤0.44         1.41           1.10     1.81        0.007
  **AGR**                                           
  ≥1.46         1.00           \-       \-          \-
  \<1.46        1.35           1.02     1.77        0.034
  **PNI**                                           
  \< 37.5       1.00           \-       \-          \-
  ≥37.5         1.19           1.02     1.39        0.026
  **ALI**                                           
  \> 47.0       1.00           \-       \-          \-
  ≤47.0         1.11           0.96     1.28        0.172
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